Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Erythropoietin in Myelodysplastic Syndrome

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Utah
ClinicalTrials.gov Identifier:
NCT00723112
First received: July 24, 2008
Last updated: November 22, 2010
Last verified: November 2010

July 24, 2008
November 22, 2010
February 2007
October 2010   (final data collection date for primary outcome measure)
Evaluate the EpoR cDNA sequence and its level of expression in the clonal erythroid progenitors of MDS patients to determine whether mutations in the EpoR may be responsible for an aberrant Epo signal transduction in MDS. [ Time Frame: After Samples are obtained ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00723112 on ClinicalTrials.gov Archive Site
  • Analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS. [ Time Frame: After samples are obtained ] [ Designated as safety issue: No ]
  • Perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins. [ Time Frame: After samples are obtained ] [ Designated as safety issue: No ]
  • Determine how often and what percent clonality occurs in MDS patients and try to predict who has early MDS by clonality testing. [ Time Frame: After samples from female patients have been obtained ] [ Designated as safety issue: No ]
  • Analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS. [ Time Frame: After samples are obtained ] [ Designated as safety issue: No ]
  • Perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins. [ Time Frame: After samples are obtained ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Role of Erythropoietin in Myelodysplastic Syndrome
The Role of Erythropoietin in Myelodysplastic Syndrome

The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.

Myelodysplastic syndromes are a heterogeneous group of disorders characterized by clonal expansion of hematopoietic stem cells and ineffective hematopoiesis. Although all 3 cell lineages in myeloid hematopoiesis can be involved, the erythroid dysplasia and ineffective erythropoiesis of MDS are usually the most severe, and often precede the development of other bone marrow lineage defects.

In normal erythropoiesis, erythroid progenitors differentiate and proliferate in response to stimulation by erythropoietin (Epo). Epo binds to its receptor, EpoR, constitutively expressed at the surface of committed erythroid progenitors and induces homodimerization. This study is designed to evaluate the EpoR cDNA sequence and its level of expression in the clonal erythroid progenitors of MDS patients (in cells stratified for the same degree of erythroid maturation) to determine whether mutations in the EpoR may be responsible for an aberrant Epo signal transduction in MDS. As well as analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS and perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects diagnosed with myelodysplastic syndrome

Myelodysplastic Syndrome
Not Provided
  • Affected Group
    Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
  • Healthy Controls
    Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
October 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult subjects greater than 18 years of age
  • Diagnosis of MDS based on the French-American-British classification system (including secondary causes of MDS)

Exclusion Criteria:

  • Subjects not meeting the criteria listed above
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00723112
20716, DK007115-31
No
Josef T. Prchal, MD, University of Utah
University of Utah
National Institutes of Health (NIH)
Principal Investigator: Josef T Prchal, MD University of Utah
University of Utah
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP